On August 18, 2026, Amylyx Pharmaceuticals reported topline results from LUCIDITY, a Phase 3 trial of avexitide in post-bariatric hypoglycemia (PBH) after Roux-en-Y gastric bypass (RYGB). The company said the trial met its FDA-agreed primary endpoint: a 55% reduction in the composite rate of Level 2 and Level 3 hypoglycemic events versus placebo (p=0.000003).
Avexitide is a GLP-1 receptor antagonist. It is designed to block GLP-1 receptors, not activate them. That is the opposite pharmacology of weight-loss drugs such as semaglutide and tirzepatide. In LUCIDITY, Amylyx reported no body-weight change in either arm over 16 weeks.
These are company topline results, not a peer-reviewed paper and not an FDA approval. Amylyx says it plans a New Drug Application by the end of 2026 and a possible 2027 launch if the drug is approved.
What happened
Amylyx announced the LUCIDITY topline on August 18, 2026. The same figures appear in the company's Form 8-K filed that day and in Exhibit 99.1, the investor-call slide deck furnished with the 8-K.
LUCIDITY (also called AVX-001) is registered as NCT06747468. ClinicalTrials.gov lists it as a Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of avexitide in PBH after RYGB. The registry currently shows the study as active, not recruiting. Primary completion is listed as July 8, 2026. Estimated completion is February 2027, which covers the open-label extension still running after the 16-week blinded period.
The company materials say 78 adults were enrolled at 21 U.S. sites and randomized 3:2 to avexitide 90 mg subcutaneously once daily or placebo for 16 weeks. ClinicalTrials.gov still prints estimated enrollment as 75. The 78-person figure is the one used in the August 18 release, the 8-K, and the Exhibit 99.1 intention-to-treat analysis.
All secondary endpoints were reported as met: Level 2 events by self-monitoring of blood glucose (SMBG), Level 2 events by continuous glucose monitoring (CGM), and independently adjudicated Level 3 events. The public topline does not give separate percentage reductions for those secondaries.
Why a GLP-1 antagonist is not a weight-loss GLP-1
Most readers who see "GLP-1" will think of agonist drugs used for type 2 diabetes and chronic weight management. Those drugs stimulate the GLP-1 receptor. They increase insulin in a glucose-dependent way, slow gastric emptying, and reduce appetite. PeptidePrices covers that class on the semaglutide and tirzepatide price pages and in the GLP-1 indications map.
Avexitide does the reverse. ClinicalTrials.gov describes it as a 31-amino-acid peptide, also known as exendin 9-39, with a free amino group at the N-terminus and an amidated C-terminus. By binding the GLP-1 receptor, it inhibits GLP-1 receptor signaling and reduces GLP-1 receptor-mediated insulin secretion.
That design matches the PBH hypothesis in Amylyx's materials. After RYGB, an exaggerated GLP-1 response to food can drive too much insulin, then a rapid drop in blood glucose. Avexitide is a competitive antagonist meant to blunt that insulin surge. It is not being developed as a weight-loss drug.
The 16-week weight result is the cleanest public check on that distinction. Amylyx said there were no changes in body weight in the avexitide arm or the placebo arm. A GLP-1 agonist trial that reported no weight change would be a surprise. Here it is consistent with receptor blockade.
Research-vendor "GLP-1" listings and compounded agonist products are not avexitide. They were not the investigational product in LUCIDITY. A COA check can tell you whether a research listing's paperwork names a real lab. It cannot turn an unapproved research vial into the Phase 3 drug.
What PBH is, and why the trial exists
PBH is recurrent hypoglycemia after bariatric surgery. Amylyx estimates it affects about 8% of people in the United States who have had sleeve gastrectomy or RYGB, or about 160,000 people. That is a company epidemiology estimate, not a census.
LUCIDITY enrolled only people with PBH after RYGB, not sleeve-only patients. The registry requires documented RYGB at least 12 months before screening, a clinical PBH diagnosis after other causes of hypoglycemia were ruled out, and at least three discrete hypoglycemic events during a three-week run-in while following dietary management.
The press release states there are currently no FDA-approved therapies for PBH. Principal investigator Marilyn Tan, of Stanford, said Level 2 and Level 3 events can cause cognitive or physical impairment, loss of consciousness, seizures, and the need for help from others. Exhibit 99.1 defines Level 2 as glucose below 54 mg/dL and Level 3 as events with altered mental or physical function that require assistance.
Those definitions matter for reading the primary endpoint. The trial did not claim to treat obesity, diabetes, or dumping syndrome as a whole. It asked whether a GLP-1 blocker reduced the rate of the most severe hypoglycemia categories versus placebo over 16 weeks.
Evidence and study design
| Item | Recorded detail | Source |
|---|---|---|
| Trial | LUCIDITY / AVX-001, NCT06747468 | ClinicalTrials.gov, company release, 8-K |
| Phase and design | Phase 3, multicenter, randomized, double-blind, placebo-controlled | Same |
| Population | Adults with PBH after RYGB | Same |
| Sites | 21 U.S. sites | Company release |
| Enrollment | Company: 78 enrolled (ITT). Registry: estimated 75 | Company release, 8-K, EX-99.1 vs ClinicalTrials.gov |
| Randomization | 3:2 avexitide versus placebo | Company release, 8-K, EX-99.1 |
| Blinded treatment | 16 weeks | Same |
| Dose in the protocol | Avexitide 90 mg subcutaneously once daily | Company release, ClinicalTrials.gov |
| Screening / run-in | Up to 6 weeks screening, including a 3-week run-in | Company release, ClinicalTrials.gov |
| Open-label extension | 32 weeks, described as two parts (8 weeks then 24 weeks) | ClinicalTrials.gov |
| Primary endpoint | Composite rate of Level 2 (SMBG) and Level 3 (independently adjudicated) events through week 16 | Company release, ClinicalTrials.gov, EX-99.1 |
| Primary result | 55% reduction versus placebo, p=0.000003 | Company release, 8-K, EX-99.1 |
| Rate ratio | 0.45 (95% CI, 0.32 to 0.63), ITT, N=78 | EX-99.1 only |
| Secondaries | Level 2 by SMBG, Level 2 by CGM, Level 3. All reported as met. No separate public percentages. | Company release, 8-K, EX-99.1 |
| Registry dates | Start April 29, 2025. Primary completion July 8, 2026. Estimated completion February 2027. | ClinicalTrials.gov |
The 55% figure and the p-value appear in the press release, the 8-K, and Exhibit 99.1. The rate ratio and confidence interval appear on the Exhibit 99.1 primary-endpoint slide. They do not appear in the prose of the press release or the 8-K body. PeptidePrices is including them because they are in the furnished SEC exhibit, not because a journal paper has confirmed them.
Exhibit 99.1 also says more than 90% of participants completed the 16-week double-blind period and that all eligible participants entered the open-label extension. Those are sponsor slides, not a published CONSORT diagram.
ClinicalTrials.gov adds protocol detail that the company release compresses. Participants used a blinded CGM, an SMBG meter, and an eDiary during screening, the 16-week blinded period, and the first 8 weeks of the extension. The registry says the CGM alerted for low glucose without showing the numeric value while blinded. During the later 24-week extension, the CGM was unblinded and SMBG and eDiary were not assessed.
The registry also lists safety, tolerability, and anti-drug antibodies among the primary outcome measures, alongside the hypoglycemia composite. The August 18 topline is an efficacy and high-level safety readout. It is not a full tables-and-listings package.
Amylyx said avexitide has now been evaluated in six PBH trials, and that LUCIDITY sits on top of five earlier studies. Those earlier datasets are not re-analyzed in this article. The Phase 3 claim stands or falls on LUCIDITY.
Safety in the blinded period
Amylyx said avexitide was generally well tolerated through the 16-week double-blind period, with a safety profile the company called consistent across completed PBH trials. Most adverse events were mild to moderate. There were no serious adverse events related to avexitide. The most common events were diarrhea, injection-site erythema, and injection-site bruising.
That is a sponsor safety summary. It is not a statement that the drug has no adverse events. It is not a long-term safety label. The 32-week open-label extension is still ongoing, and the registry's estimated completion is February 2027.
The weight finding belongs here as well as in the pharmacology section. No body-weight change in either arm over 16 weeks is evidence against reading avexitide as another GLP-1 weight-loss shot. It is also a 16-week observation in 78 people, not a metabolic-outcomes program.
Regulatory status and next filings
Avexitide is investigational. It is not FDA-approved for PBH or for any other use.
The FDA has granted Breakthrough Therapy designation for PBH. It has also granted Orphan Drug designation for hyperinsulinemic hypoglycemia, a category Amylyx says includes PBH and congenital hyperinsulinism. The company notes a Rare Pediatric Disease designation for congenital hyperinsulinism. That pediatric designation is a separate program. LUCIDITY is an adult RYGB trial.
Amylyx said it plans to submit an NDA by the end of 2026. Co-CEOs Justin Klee and Joshua Cohen said the company is preparing for a potential commercial launch in 2027 if approved. An expanded-access program launched in May remains open for eligible people, according to the company. The open-label extension remains open. Amylyx said it will present LUCIDITY at an upcoming medical meeting.
A planned NDA is not a submitted NDA. A 2027 launch date is a company target conditioned on approval. Breakthrough Therapy and Orphan Drug designations change FDA interactions and incentives. They do not approve a drug.
What this does not mean
- It is not FDA approval. LUCIDITY is a positive Phase 3 topline. Avexitide remains investigational.
- It is not a peer-reviewed result. The numbers come from a company release, an 8-K, and furnished slides. A medical-meeting presentation and a manuscript are still promised, not published.
- It is not a weight-loss GLP-1. Avexitide is a receptor antagonist. Semaglutide and tirzepatide are agonists. The trial reported no weight change in either arm.
- It is not a treatment for sleeve-only PBH in this dataset. The randomized cohort had PBH after RYGB. The company's 160,000-person U.S. estimate includes sleeve and RYGB. The Phase 3 sample does not.
- It does not publish secondary-endpoint percentages. The company said those endpoints were met. It did not release the Level 2 SMBG, Level 2 CGM, or Level 3 rate reductions in the documents reviewed here.
- It is not a consumer or research-vendor product. The 90 mg once-daily subcutaneous regimen is a trial-design figure. It is not a dosing protocol, a compounding recipe, or a research-chemical specification.
- It does not make research-market "GLP-1" peptides interchangeable with avexitide. Research listings and compounded agonists are a different market from an investigational antagonist in a controlled trial.
- Registry enrollment is not fully reconciled. ClinicalTrials.gov still shows 75 estimated. The company says 78 were enrolled and analyzed.
- "First approved PBH therapy" is an if-approved claim. There is no approved therapy today. That does not make avexitide approved tomorrow.
This article does not include a consumer dosing protocol. Milligram figures above are protocol and topline numbers from the company and the registry.
What to watch next
- The NDA clock. Amylyx says it will file by the end of 2026. Watch for an actual submission receipt, not only the plan.
- The medical-meeting presentation. The company said LUCIDITY will be presented. That is where secondary rates, baseline tables, and completeness data usually appear.
- A peer-reviewed paper. Until then, the public record is topline plus slides.
- The open-label extension. ClinicalTrials.gov lists a 32-week OLE and an estimated February 2027 completion. Durability and longer safety are still being collected.
- FDA review, if the NDA is filed. Breakthrough Therapy status can shorten interaction time. It does not predetermine the label.
- Scope beyond RYGB. Sleeve-gastrectomy PBH and congenital hyperinsulinism are mentioned in company materials. They are not this Phase 3 population.
For the agonist side of the GLP-1 map, see the ADA 2026 pipeline roundup and GLP-1 uses beyond weight loss. Those pages cover drugs that turn the receptor on. LUCIDITY is about turning it down after gastric bypass.
FAQs
What did LUCIDITY show?
Amylyx said the Phase 3 trial met its FDA-agreed primary endpoint with a 55% reduction in the composite rate of Level 2 and Level 3 hypoglycemic events versus placebo (p=0.000003). Exhibit 99.1 also reports a rate ratio of 0.45 (95% CI, 0.32 to 0.63) in the 78-person intention-to-treat analysis. All listed secondary endpoints were reported as met.
Is avexitide a weight-loss GLP-1?
No. Avexitide is an investigational GLP-1 receptor antagonist peptide (exendin 9-39). Weight-loss drugs such as semaglutide and tirzepatide are receptor agonists. LUCIDITY reported no body-weight change in either arm over 16 weeks.
Is avexitide FDA-approved?
No. The company plans an NDA by the end of 2026 and talks about a possible 2027 launch if approved. Breakthrough Therapy and Orphan Drug designations are not approvals.
Who was in the trial?
Company materials: 78 adults with PBH after RYGB, 21 U.S. sites, randomized 3:2 to avexitide 90 mg subcutaneously once daily or placebo for 16 weeks. ClinicalTrials.gov still lists estimated enrollment as 75 and requires at least three run-in hypoglycemic events despite dietary management.
Can someone buy avexitide from a research vendor?
No legitimate retail or research-vendor path makes this the LUCIDITY investigational product. Research-market GLP-1 agonist listings are a different class and were not studied here.
When will the full data appear?
Amylyx said it will present LUCIDITY at an upcoming medical meeting. A peer-reviewed manuscript is not out. The open-label extension is still running.
This article is for general informational purposes only and is not medical advice. Talk to a licensed clinician about personal medical decisions. Avexitide is an investigational peptide studied in controlled trials. Nothing here is a dosing protocol, an availability claim, or a recommendation to obtain an unapproved product.
Continue your research
- Semaglutide price comparison
- Tirzepatide price comparison
- GLP-1s Are Becoming "Everything" Drugs
- What the GLP-1 Pipeline Showed at ADA 2026
- COA Authenticity Checker
- How we rate vendors
Sources
- Amylyx Pharmaceuticals. Amylyx announces positive topline results from Phase 3 LUCIDITY clinical trial of avexitide in post-bariatric hypoglycemia. August 18, 2026
- Amylyx Pharmaceuticals, Inc. Current Report on Form 8-K. Filed August 18, 2026
- ClinicalTrials.gov NCT06747468. LUCIDITY: avexitide for treatment of post-bariatric hypoglycemia
- Amylyx Pharmaceuticals. Exhibit 99.1, Phase 3 LUCIDITY topline data conference-call slides. Furnished August 18, 2026